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Background: MB02 is a bevacizumab biosimilar developed to stringent 
guidelines, including non-clinical and preclinical investigations and a 
clinical trial as first-line treatment in metastatic colorectal cancer (Romera 
A et al. Lancet Gastroenterol Hepatol 2018;3 (12): 845-855). A clinical trial 
(STELLA) has been initiated to confirm there are no clinically meaningful 
differences between MB02 and reference bevacizumab (Avastin) in terms 
of efficacy, safety, and immunogenicity 
(NCT03296163). Methods: STELLA study is a multinational, double-blind, 
randomized, parallel-group, equivalence study comparing the efficacy and 
safety of MB02 vs reference bevacizumab plus chemotherapy in subjects 
with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). 
Subjects aged 18-80 years, with ECOG status ≤1 and histologically 
confirmed NSCLC not receiving curative intent surgery or systemic therapy 
for advanced disease are randomized (1:1) to receive: chemotherapy 
(paclitaxel 200 mg/m2 and carboplatin AUC6) and either MB02 or reference 
bevacizumab 15 mg/kg every 3 weeks for up to 6 cycles (unless disease 
progression or treatment intolerance). Randomization is stratified by sex, 
smoking status, disease diagnosis (newly/recurrent), and stage. After 6 
cycles, subjects can continue to receive MB02/reference bevacizumab in 
monotherapy every 3 weeks (until disease progression, treatment 
intolerance, death, withdrawal or end of study). The primary objective is to 
compare the objective response rate (ORR) between arms by week 18 
(independently assessed) measured by RECIST v1.1. Progression free 
survival and overall survival (at 18 and 52 weeks), safety and 
immunogenicity will be assessed as secondary objectives. A sample size 
of 600 subjects was assumed providing about 89% power to show 
equivalence of MB02 plus chemotherapy with reference bevacizumab plus 
chemotherapy on a primary endpoint of risk ratio based on ORR. To date, 
596 subjects have been recruited from more than 15 countries worldwide 
(Europe, Asia, Latin-America, Africa and Middle-East). At their last meeting 
in September, 2018 the independent data safety monitoring board (DSMB) 
recommended that the study continue without change. Clinical trial 
information: NCT03296163. 
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